Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C63H113N11O12 |
| Molecular Weight | 1216.6378 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 13 / 13 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O)C(C)C
InChI
InChIKey=OLROWHGDTNFZBH-XEMWPYQTSA-N
InChI=1S/C63H113N11O12/c1-26-29-30-40(16)52(75)51-56(79)66-44(27-2)59(82)68(20)43(19)58(81)74(28-3)49(38(12)13)55(78)67-48(37(10)11)62(85)69(21)45(31-34(4)5)54(77)64-41(17)53(76)65-42(18)57(80)70(22)46(32-35(6)7)60(83)71(23)47(33-36(8)9)61(84)72(24)50(39(14)15)63(86)73(51)25/h26,29,34-52,75H,27-28,30-33H2,1-25H3,(H,64,77)(H,65,76)(H,66,79)(H,67,78)/b29-26+/t40-,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-/m1/s1
| Molecular Formula | C63H113N11O12 |
| Molecular Weight | 1216.6378 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 13 / 13 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Alisporivir (DEBIO-025) is a first-in-class synthetic cyclophilin inhibitor, in development with Debiopharm as an oral treatment for hepatitis C virus (HCV) infections. Alisporivir has the potential to be used for the treatment of additional diseases such as other viral infections, certain muscular dystrophies, and myocardial infarction. Alisporivir has potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. It is currently being evaluated in phase II clinical trials.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. | 2006 Apr |
|
| Pharmacologic targeting or genetic deletion of mitochondrial cyclophilin D protects from NSAID-induced small intestinal ulceration in mice. | 2010 Nov |
|
| DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. | 2010 Oct 27 |
Sample Use Guides
Hepatitis C: Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT)
Route of Administration:
Oral
The 50% effective concentration for inhibition of HCV subgenomic replicon replication in Huh 5-2 cells (luciferase assay) by DEBIO-025 was 0.27 +/- 0.03 ug/mL and for CsA 2.8 +/- 0.4 ug/mL. The concentration that reduced the growth of exponentially proliferating Huh 5-2 cells by 50% was greater than 27 ug/mL for DEBIO-025 and 12 +/- 6 ug/mL for CsA, resulting in a selectivity index of approximately 900 for DEBIO-025 and 40 for CsA. DEBIO-025, at concentrations of 0.5 and 1 ug/mL, was able to clear cells from their HCV replicon within three to four passages, whereas treatment with CsA at the same concentrations for seven consecutive passages did not result in clearance of the HCV replicon.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:57:28 UTC 2023
by
admin
on
Sat Dec 16 17:57:28 UTC 2023
|
| Record UNII |
VBP9099AA6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
YY-92
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
100000126040
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
DTXSID401027752
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
8900
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
ALISPORIVIR
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
C169774
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
DB12139
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
SUB33108
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
11513676
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
VBP9099AA6
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
CHEMBL1651956
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY | |||
|
254435-95-5
Created by
admin on Sat Dec 16 17:57:29 UTC 2023 , Edited by admin on Sat Dec 16 17:57:29 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
